James La Rossa - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock James La Rossa's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
James La Rossa
Verified
Publisher and Editorial Director, MedWorks Media
Los Angeles
Beats
Government , Urban Politics, Breaking news, Urban Issues, Politics , Race And Culture
Content
By James La Rossa| MedWorks Media Verified A novel blood test that detects a key biomarker for Alzheimer’s disease (AD) could help physicians more accurately determine the presence and track disease progression. The test measures levels of the protein MTBR-tau243 — microtubule-binding region of tau containing the residue 243 — a biomarker of tau tangles in the brain that may be a more accurate measure of tau pathology than other established biomarkers.
By James La Rossa| MedWorks Media Verified Neurocrine Biosciences presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia (TD) among most patients treated with once-daily valbenazine (Ingrezza) capsules, at the 2025 Psychiatry Update Conference in Chicago.1 The conference was first reported in Psychiatric Times “These findings further establish Ingrezza as a highly effective long-term treatment option for individuals living with tardive dyskinesia, regardless of their underlying...
By James La Rossa| MedWorks Media Verified A novel blood test that detects a key biomarker for Alzheimer’s disease (AD) could help physicians more accurately determine the presence and track disease progression. The test measures levels of the protein MTBR-tau243 — microtubule-binding region of tau containing the residue 243 — a biomarker of tau tangles in the brain that may be a more accurate measure of tau pathology than other established biomarkers.
Company Info
MedWorks Media
MedWorks Media Inc. is a digital & print publisher of some of the most prominent science education journals and special educational projects, which circulate to more psychiatrists, psychopharmacologists, and the larger medical community than any other publisher in the field. Medworks' goal is to bridge cutting-edge psychiatric medicine with clinical practice, thus, meeting the highest digital standards in both medical journalism and electronic marketing. Medworks Media Inc. was founded in 1994 by it's publisher, James La Rossa. It's flagship journal, Psychopharmacology Bulletin (Thase, M.E.), has been in the Medworks library since 1999. Medworks other journals include T.E.N.– Trends in Evidence-Based Neuropsychiatry (Weissman, M), Mental Fitness (Yonkers, K), Psiquiatria y Salud Integral (Psychiatry and Integral Health, Mezzich, J), and a cancer journal, Oncology Spectrums (Von Hoff, D; Bootman, L), which specializes in integrated cancer medicine. La Rossa also founded Primary Psychiatry (1994) and CNS Spectrums (1997), two of the first psychiatric journals of their kind, both of which he sold in 2004. Medworks has the ability to tap into multiple mediums to effectively reach office and hospital-based physicians. Medwork's readers are a diverse group of professionals — from medical residents, psychiatric nurses and general practitioners — to the most heralded neuroscientists and physicians.
'+1 310-374-1300
Founded: 1994